Back for a fifth year, innovatED will be featured in the Exhibit Hall Sunday through Tuesday. Presented by Janssen Pharmaceuticals, Inc. and Allergan, this space features the latest emergency medicine technology and services presented by dozens of companies.
Explore This IssueACEP17 Sunday Daily News
Somebody has to take charge, lead, come up with something new. You can find many of the trailblazers in the Exhibit Hall at innovatED. This space features products and services that are vetted by a team of emergency physicians and showcased working together in a true-to-life environment. Engage in dialogue with company representatives and experience the current thinking, departmental design solutions, cutting-edge products and services, and best practices driving change in the emergency department. This experience is particularly valuable for those seeking ways to rebuild their emergency medicine services or bring their facility up to speed with new technologies.
Who’s driving change in emergency medicine? The people and companies listed here.
Allergan plc (NYSE: AGN) is a bold, global pharmaceutical company focused on developing, manufacturing, and commercializing branded pharmaceuticals, devices, and biologic products for patients around the world. Allergan markets leading brands and best-inclass products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology, and anti-infective therapeutic categories. Allergan is an industry leader in Open Science, the company’s research and development model, which defines its approach to developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the industry. For more information, visit Allergan’s website at www.allergan.com
Our vision is to improve the lives of the millions of people with cardiovascular disease and diabetes, and to work tirelessly to eliminate these diseases. Every year 19 million people around the world die from cardiovascular and metabolic diseases. This tremendous global burden compels us to develop new therapies that will change the face of these diseases and, ultimately, eliminate them. We focus on finding and developing truly transformational therapies that target underlying disease pathways, important pathways, and novel mechanisms of action. We have a very successful track record demonstrated by the development and recent successful launches of our products for the treatment of patients suffering from thrombosis and type 2 diabetes. And we continue to seek and develop the next generation of transformational cardiovascular and metabolic therapies.
Butterfly Network® develops handheld semiconductor-based ultrasound systems. Butterfly Network’s first product, the Butterfly iQTM for iPhone, is the world’s first personal ultrasound system. The Butterfly iQ supports cardiac, abdominal, and superficial imaging with a single wideband transducer connected to your iPhone. Butterfly Network’s Ultrasound-on-a- ChipTM technology modernizes ultrasound by delivering unparalleled diagnostic versatility at a price any clinician can afford. Your visual stethoscope has arrived. The Butterfly iQ is currently undergoing premarket review by the U.S. Food and Drug Administration.
Collective Medical Technologies